메뉴 건너뛰기




Volumn 18, Issue 16, 2012, Pages 1871-1874

Colitis associated with biological agents

Author keywords

Biological agents; Colitis; Crohn's disease; Inflammatory bowel disease; Infliximab; Ipilimumab; Rituximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BUDESONIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; ETANERCEPT; INFLIXIMAB; IPILIMUMAB; RITUXIMAB; TICILIMUMAB;

EID: 84860487320     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i16.1871     Document Type: Article
Times cited : (60)

References (43)
  • 2
    • 0027331190 scopus 로고
    • Colonic toxicity of administered medications and chemicals
    • Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993; 88: 1684-1699
    • (1993) Am J Gastroenterol , vol.88 , pp. 1684-1699
    • Cappell, M.S.1    Simon, T.2
  • 3
    • 3142772194 scopus 로고    scopus 로고
    • Colonic toxicity of administered drugs and chemicals
    • Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004; 99: 1175-1190
    • (2004) Am J Gastroenterol , vol.99 , pp. 1175-1190
    • Cappell, M.S.1
  • 9
    • 34548257760 scopus 로고    scopus 로고
    • Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
    • Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872
    • (2007) Oncologist , vol.12 , pp. 864-872
    • Weber, J.1
  • 10
    • 78449244037 scopus 로고    scopus 로고
    • The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
    • Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507
    • (2010) Semin Oncol , vol.37 , pp. 499-507
    • di Giacomo, A.M.1    Biagioli, M.2    Maio, M.3
  • 11
    • 78449256966 scopus 로고    scopus 로고
    • Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management
    • Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498
    • (2010) Semin Oncol , vol.37 , pp. 485-498
    • Kaehler, K.C.1    Piel, S.2    Livingstone, E.3    Schilling, B.4    Hauschild, A.5    Schadendorf, D.6
  • 13
    • 67349182592 scopus 로고    scopus 로고
    • Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases
    • Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58: 1297-1306
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 1297-1306
    • di Giacomo, A.M.1    Danielli, R.2    Guidoboni, M.3    Calabrò, L.4    Carlucci, D.5    Miracco, C.6    Volterrani, L.7    Mazzei, M.A.8    Biagioli, M.9    Altomonte, M.10    Maio, M.11
  • 14
    • 67650848410 scopus 로고    scopus 로고
    • Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis
    • Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24: 321-325
    • (2009) Cancer Biother Radiopharm , vol.24 , pp. 321-325
    • Minor, D.R.1    Chin, K.2    Kashani-Sabet, M.3
  • 15
    • 70350244517 scopus 로고    scopus 로고
    • Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab
    • Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540
    • (2009) Dig Dis Sci , vol.54 , pp. 2538-2540
    • Johnston, R.L.1    Lutzky, J.2    Chodhry, A.3    Barkin, J.S.4
  • 16
    • 34347250137 scopus 로고    scopus 로고
    • Rituximab in patients with the steroid-resistant nephrotic syndrome
    • Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752
    • (2007) N Engl J Med , vol.356 , pp. 2751-2752
    • Bagga, A.1    Sinha, A.2    Moudgil, A.3
  • 19
    • 0035093233 scopus 로고    scopus 로고
    • Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
    • Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211
    • (2001) Rheumatology (Oxford) , vol.40 , pp. 205-211
    • Edwards, J.C.1    Cambridge, G.2
  • 21
    • 44449172514 scopus 로고    scopus 로고
    • Rituximab and nephrotic syndrome: A new therapeutic hope?
    • Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 2008; 23: 11-17
    • (2008) Nephrol Dial Transplant , vol.23 , pp. 11-17
    • Ahmed, M.S.1    Wong, C.F.2
  • 23
    • 42549142171 scopus 로고    scopus 로고
    • Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
    • El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008; 57: 714-715
    • (2008) Gut , vol.57 , pp. 714-715
    • El Fassi, D.1    Nielsen, C.H.2    Kjeldsen, J.3    Clemmensen, O.4    Hegedüs, L.5
  • 25
    • 34447121952 scopus 로고    scopus 로고
    • Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
    • Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2007; 2: 571-573
    • (2007) J Thorac Oncol , vol.2 , pp. 571-573
    • Gray, J.1    Murren, J.2    Sharma, A.3    Kelley, S.4    Detterbeck, F.5    Bepler, G.6
  • 26
    • 34247513403 scopus 로고    scopus 로고
    • Beva-cizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer
    • Adenis A, Vanseymortier L, Foissey D, Colombel JF. Beva-cizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut 2007; 56: 734
    • (2007) Gut , vol.56 , pp. 734
    • Adenis, A.1    Vanseymortier, L.2    Foissey, D.3    Colombel, J.F.4
  • 27
    • 38649096270 scopus 로고    scopus 로고
    • "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy
    • August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 2008; 97: 180-185
    • (2008) J Surg Oncol , vol.97 , pp. 180-185
    • August, D.A.1    Serrano, D.2    Poplin, E.3
  • 28
    • 42449136217 scopus 로고    scopus 로고
    • Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery
    • Abbrederis K, Kremer M, Schuhmacher C. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. Chirurg 2008; 79: 351-355
    • (2008) Chirurg , vol.79 , pp. 351-355
    • Abbrederis, K.1    Kremer, M.2    Schuhmacher, C.3
  • 30
    • 34248569455 scopus 로고    scopus 로고
    • Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents
    • Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-647
    • (2007) Arthritis Rheum , vol.57 , pp. 639-647
    • Braun, J.1    Baraliakos, X.2    Listing, J.3    Davis, J.4    van der Heijde, D.5    Haibel, H.6    Rudwaleit, M.7    Sieper, J.8
  • 31
    • 36249008568 scopus 로고    scopus 로고
    • Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis
    • Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26: 2205-2206
    • (2007) Clin Rheumatol , vol.26 , pp. 2205-2206
    • Vandevyvere, K.1    Luyten, F.P.2    Verschueren, P.3    Lories, R.4    Segaert, S.5    Westhovens, R.6
  • 33
    • 34547543928 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha inhibitor associated ulcerative colitis
    • Prescott K, Costner M, Cohen S, Kazi S. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci 2007; 333: 137-139
    • (2007) Am J Med Sci , vol.333 , pp. 137-139
    • Prescott, K.1    Costner, M.2    Cohen, S.3    Kazi, S.4
  • 34
    • 50649105058 scopus 로고    scopus 로고
    • Onset of ulcerative colitis under treatment with adalimumab
    • Tursi A, Penna A. Onset of ulcerative colitis under treatment with adalimumab. Am J Gastroenterol 2008; 103: 2410-2412
    • (2008) Am J Gastroenterol , vol.103 , pp. 2410-2412
    • Tursi, A.1    Penna, A.2
  • 36
    • 0037214122 scopus 로고    scopus 로고
    • Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis
    • Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-76
    • (2003) Ann Rheum Dis , vol.62 , pp. 74-76
    • Marzo-Ortega, H.1    McGonagle, D.2    O'Connor, P.3    Emery, P.4
  • 37
    • 13644269425 scopus 로고    scopus 로고
    • Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis
    • Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004; 39: 203-206
    • (2004) J Pediatr Gastroenterol Nutr , vol.39 , pp. 203-206
    • Ruemmele, F.M.1    Prieur, A.M.2    Talbotec, C.3    Goulet, O.4    Schmitz, J.5
  • 38
    • 54949118761 scopus 로고    scopus 로고
    • Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)
    • Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioǧlu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008; 10: 953-954
    • (2008) Colorectal Dis , vol.10 , pp. 953-954
    • Yazisiz, V.1    Avci, A.B.2    Erbasan, F.3    Yildirim, B.4    Terzioǧlu, E.5
  • 40
    • 70450222544 scopus 로고    scopus 로고
    • Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: Possible mechanisms of action
    • Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009; 39: 176-181
    • (2009) Semin Arthritis Rheum , vol.39 , pp. 176-181
    • Haraoui, B.1    Krelenbaum, M.2
  • 41
    • 48049110733 scopus 로고    scopus 로고
    • Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment
    • Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, Akkoc N. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912-2914
    • (2008) World J Gastroenterol , vol.14 , pp. 2912-2914
    • Sari, I.1    Birlik, M.2    Gonen, C.3    Akar, S.4    Gurel, D.5    Onen, F.6    Akkoc, N.7
  • 42
    • 84859601793 scopus 로고    scopus 로고
    • Colitis as a manifestation of infliximabassociated disseminated cryptococcosis
    • Osawa R, Singh N. Colitis as a manifestation of infliximabassociated disseminated cryptococcosis. Int J Infect Dis 2010; 14: e436-e440
    • (2010) Int J Infect Dis , vol.14
    • Osawa, R.1    Singh, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.